ACADIA Pharmaceuticals Company Insiders
ACAD Stock | USD 16.74 0.25 1.47% |
ACADIA Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding ACADIA Pharmaceuticals suggests that all insiders are panicking. ACADIA Pharmaceuticals employs about 597 people. The company is managed by 43 executives with a total tenure of roughly 219 years, averaging almost 5.0 years of service per executive, having 13.88 employees per reported executive.
Leslie Iversen Chairman Independent Chairman of the Board |
Stephen Davis President Executive Vice President CFO and Chief Business Officer |
ACADIA Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-04-08 | Brendan Teehan | Disposed 2568 @ 17.87 | View | ||
2024-03-27 | Stephen Davis | Disposed 17714 @ 17.9 | View | ||
2024-02-26 | Stephen Davis | Disposed 5577 @ 24.67 | View | ||
2024-01-08 | Stephen Davis | Disposed 3732 @ 29.96 | View | ||
2023-12-15 | James Kihara | Disposed 2000 @ 28.3 | View | ||
2023-11-20 | James Kihara | Disposed 1985 @ 22.64 | View | ||
2023-10-06 | Stephen Davis | Disposed 51563 @ 21.96 | View |
Monitoring ACADIA Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ACADIA |
ACADIA Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ACADIA Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that ACADIA will maintain a workforce of about 600 employees by May 2024.ACADIA Pharmaceuticals' latest congressional trading
Congressional trading in companies like ACADIA Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in ACADIA Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
2022-06-16 | Representative Chris Jacobs | Disposed Under $15K | Verify | ||
2019-02-19 | Representative Gilbert Cisneros | Disposed Under $15K | Verify |
ACADIA Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0686) % which means that it has lost $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1473) %, meaning that it created substantial loss on money invested by shareholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 41 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.6 M.The current year's Common Stock Shares Outstanding is expected to grow to about 172 M, whereas Net Loss is forecasted to decline to (204.1 M).
ACADIA Pharmaceuticals Workforce Comparison
ACADIA Pharmaceuticals is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 5,361. ACADIA Pharmaceuticals retains roughly 597 in number of employees claiming about 11% of equities under Health Care industry.
ACADIA Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.74 | 0.937 |
|
|
ACADIA Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ACADIA Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.5 | 6 | 12 | 65,797 | 99,445 |
2024-03-01 | 1.1176 | 19 | 17 | 765,674 | 67,483 |
2023-12-01 | 0.6923 | 9 | 13 | 168,342 | 241,351 |
2023-09-01 | 0.1667 | 1 | 6 | 100,000 | 283,602 |
2023-06-01 | 1.7429 | 61 | 35 | 1,951,536 | 238,828 |
2023-03-01 | 0.65 | 13 | 20 | 359,357 | 94,973 |
2022-12-01 | 0.8333 | 5 | 6 | 37,996 | 21,134 |
2022-06-01 | 2.8333 | 34 | 12 | 1,486,512 | 46,155 |
2022-03-01 | 1.0667 | 16 | 15 | 60,640 | 33,538 |
2021-12-01 | 0.3125 | 5 | 16 | 70,668 | 208,313 |
2021-06-01 | 2.625 | 21 | 8 | 182,704 | 45,656 |
2021-03-01 | 1.3636 | 30 | 22 | 725,687 | 239,251 |
2020-12-01 | 0.5 | 5 | 10 | 26,406 | 43,388 |
2020-09-01 | 1.0 | 5 | 5 | 37,952 | 54,500 |
2020-06-01 | 0.75 | 30 | 40 | 585,154 | 1,071,679 |
2020-03-01 | 18.5 | 37 | 2 | 1,468,274 | 20,000 |
2019-12-01 | 0.4375 | 14 | 32 | 491,572 | 972,270 |
2019-09-01 | 0.8182 | 9 | 11 | 1,620,967 | 121,579 |
2019-06-01 | 3.0 | 15 | 5 | 754,512 | 504,256 |
2019-03-01 | 0.3333 | 1 | 3 | 10,000 | 120,000 |
2018-12-01 | 1.2727 | 14 | 11 | 12,264,484 | 545,843 |
2018-03-01 | 1.1429 | 8 | 7 | 159,500 | 285,379 |
2017-12-01 | 0.7 | 7 | 10 | 1,505,468 | 1,600,366 |
2017-09-01 | 1.625 | 13 | 8 | 682,301 | 144,352 |
2017-06-01 | 2.3333 | 7 | 3 | 105,996 | 17,899 |
2017-03-01 | 0.9375 | 15 | 16 | 1,066,504 | 416,942 |
2016-12-01 | 0.625 | 5 | 8 | 44,135 | 74,135 |
2016-09-01 | 2.25 | 9 | 4 | 1,520,030 | 22,682 |
2016-06-01 | 3.2 | 16 | 5 | 562,573 | 145,086 |
2016-03-01 | 12.5 | 25 | 2 | 7,390,602 | 14,000 |
2015-12-01 | 2.3333 | 7 | 3 | 310,000 | 44,000 |
2015-09-01 | 1.3333 | 4 | 3 | 250,500 | 25,500 |
2015-06-01 | 12.0 | 12 | 1 | 140,627 | 7,627 |
2015-03-01 | 1.1053 | 21 | 19 | 833,975 | 305,170 |
2014-12-01 | 0.65 | 13 | 20 | 246,060 | 394,120 |
2014-09-01 | 0.6316 | 12 | 19 | 581,882 | 408,764 |
2014-06-01 | 1.0417 | 25 | 24 | 310,592 | 359,184 |
2014-03-01 | 1.0588 | 18 | 17 | 1,345,316 | 456,000 |
2013-12-01 | 0.6667 | 14 | 21 | 229,309 | 383,118 |
2013-09-01 | 0.8214 | 23 | 28 | 624,016 | 798,761 |
2013-06-01 | 1.4 | 63 | 45 | 5,622,301 | 1,306,412 |
2013-03-01 | 0.7778 | 7 | 9 | 55,500 | 40,500 |
2012-12-01 | 0.5 | 3 | 6 | 43,631 | 70,602 |
2012-09-01 | 1.0 | 4 | 4 | 59,166 | 59,166 |
2010-03-01 | 0.5714 | 4 | 7 | 900,000 | 110,000 |
2009-09-01 | 1.0 | 2 | 2 | 20,000 | 20,000 |
2008-09-01 | 1.3333 | 4 | 3 | 22,000 | 21,000 |
2008-03-01 | 1.4167 | 17 | 12 | 263,000 | 36,000 |
2007-12-01 | 0.1818 | 4 | 22 | 23,500 | 62,000 |
2007-09-01 | 0.1212 | 4 | 33 | 12,500 | 57,528 |
2007-06-01 | 1.8571 | 13 | 7 | 101,308 | 48,834 |
2006-12-01 | 1.0 | 1 | 1 | 3,000 | 3,000 |
2006-09-01 | 0.6667 | 4 | 6 | 130,916 | 37,000 |
2006-06-01 | 6.5 | 13 | 2 | 210,014 | 28,000 |
2006-03-01 | 0.3636 | 4 | 11 | 122,000 | 106,000 |
2005-12-01 | 0.3333 | 2 | 6 | 40,500 | 65,500 |
2005-09-01 | 2.5 | 10 | 4 | 163,900 | 44,000 |
2004-06-01 | 0.7813 | 25 | 32 | 7,625,385 | 3,789,195 |
ACADIA Pharmaceuticals Notable Stakeholders
An ACADIA Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ACADIA Pharmaceuticals often face trade-offs trying to please all of them. ACADIA Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ACADIA Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephen JD | CEO President | Profile | |
Leslie Iversen | Independent Chairman of the Board | Profile | |
Stephen Davis | Executive Vice President CFO and Chief Business Officer | Profile | |
Michael Yang | Executive Vice President Chief Commercial Officer | Profile | |
Austin Kim | Executive Vice President General Counsel, Secretary | Profile | |
Todd Young | CFO, Executive Vice President Principal Financial Officer and Principal Accounting Officer | Profile | |
Srdjan Stankovic | Executive Vice President Head - Research and Development | Profile | |
Mark Johnson | Vice President Investor Relations | Profile | |
Elena Ridloff | Interim CFO, Senior Vice President | Profile | |
Mark Schneyer | Executive CFO | Profile | |
Glenn Baity | Executive VP, General Counsel and Secretary | Profile | |
Terrence Moore | Chief Commercial Officer and Executive VP | Profile | |
Mary Gray | Independent Director | Profile | |
Daniel Soland | Director | Profile | |
William Wells | Independent Director | Profile | |
Edmund Harrigan | Director | Profile | |
Lisa Barthelemy | Director of Investor Relations | Profile | |
Laura Brege | Independent Director | Profile | |
James Daly | Director | Profile | |
Julian Baker | Director | Profile | |
Michael Borer | Independent Director | Profile | |
Stephen Biggar | Independent Director | Profile | |
Jim Daly | Director | Profile | |
Jennifer JD | Chief VP | Profile | |
MPH MD | Global SVP | Profile | |
Parag PharmD | Senior Franchise | Profile | |
Bob Mischler | Senior Strategy | Profile | |
Douglas MD | Executive Development | Profile | |
James Kihara | Chief VP | Profile | |
Rob Ackles | Senior Officer | Profile | |
Julie Fisher | Senior Strategy | Profile | |
Erika Zavod | Planning, Strategy | Profile | |
Kevin Oliver | Senior Officer | Profile | |
Benir Ruano | Senior Operations | Profile | |
Elizabeth Thompson | Executive Development | Profile | |
Albert Kildani | Senior Communications | Profile | |
Eric Miller | Principal Accounting Officer, Controller | Profile | |
Kimberly Manhard | Senior Execution | Profile | |
MSPH MD | President | Profile | |
Holly Valdiviez | Senior Sales | Profile | |
Brendan Teehan | COO VP | Profile | |
Sanjeev MD | Senior Development | Profile | |
Stephanie Kim | Senior Affairs | Profile |
About ACADIA Pharmaceuticals Management Performance
The success or failure of an entity such as ACADIA Pharmaceuticals often depends on how effective the management is. ACADIA Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACADIA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACADIA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.09) | |
Return On Capital Employed | (0.15) | (0.16) | |
Return On Assets | (0.08) | (0.09) | |
Return On Equity | (0.14) | (0.15) |
The data published in ACADIA Pharmaceuticals' official financial statements usually reflect ACADIA Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ACADIA Pharmaceuticals. For example, before you start analyzing numbers published by ACADIA accountants, it's critical to develop an understanding of what ACADIA Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ACADIA Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ACADIA Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ACADIA Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.
ACADIA Pharmaceuticals Workforce Analysis
Traditionally, organizations such as ACADIA Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ACADIA Pharmaceuticals within its industry.ACADIA Pharmaceuticals Manpower Efficiency
Return on ACADIA Pharmaceuticals Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 16.9M | |
Net Loss Per Employee | 102.7K | |
Net Loss Per Executive | 1.4M | |
Working Capital Per Employee | 606.1K | |
Working Capital Per Executive | 8.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.